Mantle cell lymphoma trials in Italy

In Italy 17 Also abroad 150

17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Where
Alessandria, Bergamo, Bologna, Milan, Turin
Age
18 years and over
People
182 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06084936
Phase 1Taking people
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Where
Bologna, Naples, Rozzano
Age
18 years and over
People
215 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07101328 · EU 2025-524180-20-00
Phase 2Taking people
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with Mantle Cell Lymphoma.
Where
Alexandria, Bologna, Brescia, Catania, Cuneo, Florence, Genoa, Milan, Novara, Pavia, Piacenza, Rimini, Rome, Trieste, Turin, Verona
Age
18 years and over
People
235 worldwide
Run by
Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR
See details and how to join2022-501808-96-00 · EU 2022-501808-96-00
Phase 1Taking people
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Where
Candiolo, Milan
Age
18 years and over
People
140 worldwide
Run by
Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659
Phase 1Taking people
A Study of ARC-02 in B-cell NHL
Where
Aviano, Bergamo, Bologna, Rozzano
Age
18 years and over
People
140 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Where
Bologna, Lecce, Meldola, Trieste, Verona
Age
18 years and over
People
300 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06742996 · EU 2024-515593-27-00
Phase 1/2Taking people
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Where
Bologna, Milan
Age
18 years and over
People
408 worldwide
Run by
AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00
Phase 2Taking people
Study carried out at multiple centers to test Glofitamab in patients with mantle cell lymphoma who did not respond well to, or relapsed after, CAR T-cell therapy.
Where
Alexandria, Bologna, Brescia, Florence, Genoa, Milan, Palermo, Pescara, Pisa, Reggio Calabria, Rome, Turin, Verona, Vicenza
Age
18 years and over
People
41
Run by
Fondazione Italiana Linfomi Ets
See details and how to join2025-523428-39-00 · EU 2025-523428-39-00
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Bologna, Milan, Roma, Verona
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 1/2Taking people
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Where
Bologna, Milan
Age
18 years and over
People
174 worldwide
Run by
AstraZeneca
See details and how to joinNCT06542250
Phase 3Taking people
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Where
Alexandria, Bergamo, Bologna, Milan, Turin
Age
18 years and over
People
39 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2023-503206-37-00 · EU 2023-503206-37-00
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Bologna, Brescia, Milan, Rome
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
Phase 2Taking people
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Where
Alessandria, Bologna, Brescia, Florence, Genova, Milan, Palermo, Pescara, Pisa, Reggio Calabria, Roma, Torino, Verona, Vicenza
Age
18 years and over
People
41
Run by
Fondazione Italiana Linfomi - ETS
See details and how to joinNCT07453095
Phase 2Taking people
PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)
Where
Ancona, Avellino, Bologna, Brescia, Catania, Meldola, Milan, Palermo, Parma, Pescara, Piacenza, Ponderano, Reggio Emilia, Rozzano, Siena, Terni, Treviso, Varese, Verona, Vicenza
Age
65 years and over
People
56
Run by
Fondazione Italiana Linfomi Ets
See details and how to join2025-521666-10-01 · EU 2025-521666-10-01
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
Alexandria, Milan, Turin, Verona
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00
Phase 2Not yet taking people in Italy
PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma
Where
Ancona, Avellino, Biella, Bologna, Brescia, Catania, Meldola, Milan, Palermo, Parma, Pescara, Piacenza, Reggio Emilia, Rozzano, Siena, Terni, Treviso, Varese, Verona, Vicenza
Age
70 years and over
People
56
Run by
Fondazione Italiana Linfomi - ETS
See details and how to joinNCT07207785
No phaseTaking people
Italian Observational Study on CAR-T Therapy for Lymphoma
Where
Milan
Age
18 years and over
People
5,300
Run by
Paolo Corradini
See details and how to joinNCT06339255